APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES
Abstract
financing of rare disease drugs remains a serious problem for both foreign countries and our country. A limited budget for treatment of such patients determines significant difficulties for its distribution as part of drug supply to rare disease patients. The introduction of multiple-criteria analysis for identifying priority areas for financing diseases can be considered as one of the approaches to increase objectivity and transparency of decisions in the area of rare diseases. The main advantage of multiple-criteria analysis is the comprehensiveness of decisions: this type of analysis can provide consideration of disease severity and treatment efficacy. In 2014, a pilot study was conducted in the Russian Federation which involved 85 experts in various fields of medicine (clinical medicine, health financing, health management, scientific activity), which demonstrated that, from the point of view of experts, the characteristics of treatment are more important for identification of rare disease funding priority than the characteristics of the disease itself.
About the Authors
V. V. Omelyanovskiy
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
V. K. Fedyaeva
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
O. Yu. Rebrova
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Omel'yanovskii V.V., Sura M.V., Gerasimova K.V., Avksent'eva M.V., Tatarinov A.P. Assessment of the necessary financial costs medicinal maintenance of patients with rare diseases in Russia. Newsletter. Expert Health Council of the Federation Council Committee on Social Policy of the Federal Assembly of the Russian Federation, 2014 [Otsenka neobkhodimykh finansovykh zatrat na lekarstvennoe obespechenie bol'nykh s redkimi zabolevaniyami v RF. Informatsionnyi byulleten'. Ekspertnyi sovet po zdravookhraneniyu komiteta Soveta Federatsii po sotsial'noi politike Federal'nogo Sobraniya RF, 2014 g].
2. Omel'yanovskii V.V., Fedyaeva V.K., Rebrova O.Yu. Guidelines on the application of multi-criteria analysis in health care. Expert Health Council of the Federation Council Committee on Social Policy, Research Institute of Finance Ministry of Finance, 2014 [Metodicheskie rekomendatsii po primeneniyu mnogokriterial'nogo analiza v zdravookhranenii. Ekspertnyi sovet po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial'noi politike, Nauchno-issledovatel'skii finansovyi institut Ministerstva finansov RF, 2014 g].
3. Government Decree of 26.04.2012 N 403 (ed. By 04.09.2012) «On the order of the Federal Register of persons suffering from lifethreatening and chronic progressive rare (orphan) diseases that can shorten life expectancy of citizens or their disability, and regional segment «(with the» Rules of conducting the federal register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases that can shorten life expectancy of citizens or their disability and its regional segment «) [Postanovlenie Pravitel'stva RF ot 26.04.2012 N 403 (red. ot 04.09.2012) «O poryadke vedeniya Federal'nogo registra lits, stradayushchikh zhizneugrozhayushchimi i khronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ikh invalidnosti, i ego regional'nogo segmenta» (vmeste s «Pravilami vedeniya Federal'nogo registra lits, stradayushchikh zhizneugrozhayushchimi i khronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ikh invalidnosti, i ego regional'nogo segmenta»)].
4. Government Decree of 28.08.2014 N 871 «On approval of the formation of lists of drugs for medical use and a minimum range of medicines required for medical care» [Postanovlenie Pravitel'stva RF ot 28.08.2014 N 871 «Ob utverzhdenii Pravil formirovaniya perechnei lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal'nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoi pomoshchi»].
5. The Federal Law of 21.11.2011 N 323-FZ (ed. By 28.12.2013) «On the basis of the health of citizens in the Russian Federation» [Federal'nyi zakon ot 21.11.2011 N 323-FZ (red. ot 28.12.2013) «Ob osnovakh okhrany zdorov'ya grazhdan v Rossiiskoi Federatsii»].
6. Fedyaeva i soavt. Meditsinskie tekhnologii. Otsenka i vybor. 2014; 2: 30-35.
7. Diaby V., Campbell K., Goeree R. Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. Operations Research for Health Care. 2013; 2 (1): 20-24.
8. Diaby V., Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-bystep guide. Expert review of pharmacoeconomics & outcomes research. 2014; 14 (1): 81-99.
9. Drugs for Rare Diseases: Evolving Trends in Regulatory and Health Technology Assessment Perspectives. Canadian Agency for Drugs and Technologies in Health. Issue 24 October 2013. // Link: http://www.cadth.ca/media/pdf/ES0281_RareDiseaseDrugs_es_e.pdf (dostup 5 fevralya 2015 g.)
10. Fedyaeva V.K., Omelyanovsky V.V., Rebrova O., Khan N., Petrovskaya E.V. MCDA Approach To Ranking Rare Diseases In Russia: Preliminary Results. Value in Health Volume 16, Issue 7 (November 2013) A599.
11. Goetghebeur M.M. et al. Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications. BMC Health Services Research. 2008; 8 (1): 270.
12. Hughes-Wilson W., Palma A., Schuurman A., Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012; 7 (1): 74.
13. Multi-Criteria Decision Analysis in Health Technology Assessments of Orphan Drugs // Link: http://www.shire.com/shireplc/dlibrary/documents/DecisionAnalysisinHTAOrphanDrugs.pdf (dostup 5 fevralya 2015 g.)
14. Simoens S. Health technologies for rare diseases: does conventional HTA still apply? Expert Rev. Pharmacoecon. Outcomes Res. 2014; 14 (3): 315-317.
15. Sussex J., Rollet P., Garau M. et al. Multi-criteria decision analysis to value orphan medicines. Office of Health Economics. London. 2013.
For citation:
Omelyanovskiy V.V., Fedyaeva V.K., Rebrova O.Y. APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(4):29-35. (In Russ.)
Views: 520
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 